PTAB Tracker

Abatacept (Orencia)+

U.S. Patent 8,476,239
Patent Owner: Bristol-Myers Squibb
Title: Stable Protein Formulations

IPR2015-01537, filed by Momenta

Adalimumab (Humira)+

U.S. Patent 8,889,135
Patent Owner: Abbvie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa-antibodies

IPR2016-00408, filed by Boehringer Ingelheim

IPR2016-00409, filed by Boehringer Ingelheim

IPR2016-00172, filed Coherus BioSciences, Inc.

U.S. Patent 9,017,680
Patent Owner: Abbvie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa antibodies

IPR2016-00188, filed by Coherus BioSciences

U.S. Patent 9,073,987
Patent Owner: AbbVie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa antibodies

IPR2016-00189, filed by Coherus BioSciences

U.S. Patent 9,085,619
Patent Owner:  Abbvie Biotechnology
Title: Anti-TNF Antibody Formulations

IPR2017-01009, filed by Coherus BioSciences, Inc.

IPR2017-01008, filed by Coherus

IPR2017-00822, filed by Coherus BioSciences, Inc.

IPR2017-00823, filed by Coherus BioSciences, Inc.

IPR2017-00826, filed by Coherus BioSciences, Inc.

  • Filing date: January 31, 2017
  • Status: Unopposed motion to dismiss petitions without prejudice filed by petitioner on April 7, 2017 and granted on April 11, 2017
  • Petition

IPR2017-00827, filed by Coherus BioSciences, Inc.

  • Filing date: January 31, 2017
  • Status: Unopposed motion to dismiss petitions without prejudice filed by petitioner on April 7, 2017 and granted on April 11, 2017
  • Petition

U.S. Patent 8,802,100
Patent Owner:  AbbVie  Biotechnology
Title:  Formulation of human antibodies for treating TNF-alpha associated disorders

IPR2017-01823, filed by Sandoz

U.S. Patent 9,512,216
Patent Owner:  AbbVie Biotechnology
Title:  Use of TNFa Inhibitor

IPR2017-01824, filed by Sandoz

IPR2018-00002, filed by Sandoz

U.S. Patent 8,911,737
Patent Owner: AbbVie Biotechnology
Title: Methods of administering anti-TNFa antibodies

IPR2017-01987, filed by Sandoz

IPR2017-01988, filed by Sandoz

U.S. Patent 9,090,689
Patent Owner: AbbVie Biotechnology
Title: Use of TNFa inhibitor for treatment of psoriasis

IPR2017-02105, filed by Sandoz

U.S. Patent 9,067,992
Patent Owner:  AbbVie Biotechnology
Title:  Use of TNFa inhibitor for treatment of psoriatic arthritis

IPR2017-02106, filed by Sandoz

U.S. Patent 8,916,157
Patent Owner:  AbbVie Biotechnology
Title:  Formulation of human antibodies for treating TNF-a associated disorders

IPR2015-01514, filed by Amgen

U.S. Patent 8,916,158
Patent Owner: AbbVie Biotechnology
Title: Formulation of Human Antibodies for Treating RNF-a Associated Disorders

IPR2015-01517, filed by Amgen

U.S. Patent 9,114,166
Patent Owner: AbbVie Biotechnology
Title:  Formulation of Human Antibodies for Treating TNF-a Associated Disorders

IPR2016-01018, filed by Coherus

U.S. Patent 9,187,559
Patent Owner: Abbvie Biotechnology
Title:  Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease

IPR2018-00156, filed by Sandoz

Bevacizumab (Avastin)+

U.S. Patent 7,622,115
Patent Owner:  Genentech
Title: Treatment with anti-VEGF antibodies

IPR2016-01771, filed by Hospira

U.S. Patent 9,795,672
Patent Owner: Genentech
Title: Treatment with Anti-VEGF Antibodies

IPR2018-00373, filed by Pfizer

  • Filing date: January 5, 2018
  • Status: Institution pending as of January 5, 2018.
  • Petition

Dupilumab (Dupixent)+

U.S. Patent 8,679,487
Patent Owner: Immunex Corp.
Title: Anti-interleukin-4 receptor antibodies

IPR2017-01879, filed by Sanofi-Aventis

IPR2017-01129, filed by Sanofi Aventis

IPR2017-01884, filed by Sanofi Aventis

Etanercept (Enbrel)+

U.S. Patent 8,163,522
Patent Owner:  Hoffman-Laroche
Title:  Human TNF receptor

IPR2017-01916, filed by Coherus

IPR2015-01792, filed by Coalition for Affordable Drugs

U.S. Patent 8,063,186
Patent Owner: Genentech
Title: Antibodies to PRO7436 polypeptides

IPR2017-02066, filed by Coherus

Insulin Glargine (Lantus)+

Insulin Glargine (Lantus)

U.S. Patent 7,476,652
Patent Owner: Sanofi
Title: Acidic Insulin Preparations having Improved Stability

IPR2017-01526, filed by Mylan

IPR2017-01528, filed by Mylan

U.S. Patent No. 8,603,044
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01675, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

IPR2018-01676, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

U.S. Patent No. 8,679,069
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01670, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

U.S. Patent No. 8,992,486
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01677 , filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

IPR2018-01678, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

IPR2018-01696, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

U.S. Patent No. 9,526,844
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01680, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

IPR2018-01682, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

IPR2018-01696, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

U.S. Patent No. 9,604,008
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01684, filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petition pending.
  • Petition

U.S. Patent No. 8,992,486
Patent Owner: Sanofi
Title: Pen-type injector

IPR2019-00122, filed by Mylan

  • Filing date: October 29, 2018
  • Status: Petition pending.
  • Petition

Natalizumab (Tysabri)+

U.S. Patent 8,815,236
Patent Owner: Biogen
Title: Method for Treating Multiple Sclerosis and Crohn’s Disease

IPR2016-00912, filed by Swiss Pharma

U.S. Patent 8,349,321
Patent Owner: Biogen
Title:  Immunoglobin Formulation and Method of Preparation Thereof

IPR2016-00915, filed by Swiss Pharma

U.S. Patent 8,900,577
Patent Owner: Biogen
Title: Immunoglobulin Formulation and Method of Preparation thereof

IPR2016-00916, filed by Swiss Pharma

Pegfilgrastim (Neulasta)+

U.S. Patent 8,952,138
Patent Owner: Amgen
Title: Refolding proteins using a chemically controlled redox state

IPR2016-01542, filed by Apotex

U.S. Patent 9,856,287
Patent Owner: Amgen
Title: Refolding proteins using a chemically controlled redox state

PGR2019-00001, filed by Adello Biologics, LLC

  • Filing date: October 1, 2018
  • Status: Petition pending.
  • Petition

Rituximab (Rituxan)+

U.S. Patent 7,820,161
Patent Owner: Biogen
Title: Treatment of Autoimmune Diseases

IPR2016-01614, filed by Celltrion

IPR2017-01115, filed by Pfizer

IPR2015-00415, filed by Boehringer Ingelheim

IPR2015-01744, filed by Celltrion

  • Filing date: August 17, 2015
  • Status: Terminated prior institution following motion to dismiss by petitioner on October 6, 2015.
  • Petition

U.S. Patent 7,976,838
Patent Owner: Genentech
Title: Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNFa inhibitor

IPR2016-01667, filed by Celltrion

IPR2017-02042, filed by Sandoz

IPR2017-02036, filed by Sandoz

IPR2017-01923, filed by Pfizer

IPR2015-00417, filed by Boehringer Ingelheim

IPR2015-01733, filed by Celltrion

  • Filing date: August 14, 2015
  • Status: Terminated prior to institution following motion to dismiss by petitioner on October 6, 2015.
  • Petition

IPR2018-01019, filed by Celltrion

  • Filing date: May 4, 2018
  • Status: Institution and Motion for joinder with IPR2017-01923 pending as of May 4, 2018.
  • Petition

U.S. Patent 8,329,172
Patent Owner:  Biogen
Title:  Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody

IPR2017-01093, filed by Celltrion

IPR2017-01166, filed by Pfizer

IPR2015-00418, filed by Boehringer Ingelheim

IPR2018-00285, filed by Pfizer

U.S. Patent 8,557,244
Patent Owner: Biogen
Title:  Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody

IPR2017-01094, filed by Celltrion

IPR2017-01167, filed by Pfizer

U.S. Patent 9,296,821
Patent Owner: Biogen
Title: Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies

IPR2017-01095, filed by Celltrion

IPR2018-00186, filed by Pfizer

U.S. Patent 7,682,612
Patent Owner:  Genentech
Title:  Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody

IPR2017-01227, filed by Celltrion

IPR2017-01230, filed by Celltrion

IPR2017-02126, filed by Pfizer

U.S. Patent 8,206,711
Patent Owner: Genentech
Title: Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies

IPR2017-01229, filed by Celltrion

IPR2017-02127, filed by Pfizer

U.S. Patent 8,821,873
Patent Owner: Biogen
Title: Treatment of Diffuse Large-cell Lymphoma with Anti-CD20 Antibody

IPR2017-01168, filed by Pfizer

U.S. Patent 8,545,843
Patent Owner: Biogen
Title: Treatment of Vasculitis

IPR2018-00086, Petitioner: Pfizer

U.S. Patent 9,504,744
Patent Owner: Biogen
Title: Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody

IPR2018-00231, filed by Pfizer

Trastuzumab (Herceptin)+

U.S. Patent 6,407,213
Patent Owner: Genentech
Title: Methods for Making humanized antibodies

IPR2017-02139, filed by Samsung Bioepis

IPR2017-02140, filed by Samsung Bioepis

IPR2017-02031, filed by Boehringer Ingelheim

IPR2017-02032, filed by Boehringer Ingelheim

IPR2017-01488, filed by Pfizer

IPR2017-01489, filed by Pfizer

IPR2017-01373, filed by Celltrion

IPR2017-01374, filed by Celltrion

IPR2016-01693, filed by Mylan

IPR2016-01694, filed by Mylan

U.S. Patent 7,846,441
Patent Owner: Genentech
Title: Treatment with Anti-ErbB2 Antibodies

IPR2017-01121, filed by Celltrion

IPR2017-00731, filed by Pfizer

IPR2018-00016, filed by Pfizer

IPR2017-02063, filed by Pfizer

IPR2018-00192, filed by Samsung Bioepis

U.S. Patent 7,892,549
Patent Owner: Genentech
Title:  Treatment with Anti-ErbB2 Antibodies

IPR2017-01122, filed by Celltrion

IPR2017-00737, filed by Pfizer

IPR2017-00739, filed by Pfizer

IPR2017-01960, filed by Samsung Bioepis

U.S. Patent 6,627,196
Patent Owner: Genentech
Title: Dosages for Treatment with Anti-ErbB2 Antibodies

IPR2017-01139, filed by Celltrion

IPR2017-00804, filed by Pfizer

IPR2017-01958, filed by Samsung Bioepis

U.S. Patent 7,371,379
Patent Owner: Genentech
Title:  Dosages for Treatment with  Anti-ErbB2 Antibodies

IPR2017-01140, filed by Celltrion

IPR2017-00805, filed by Pfizer

IPR2017-01959, filed by Samsung Bioepis

U.S. Patent 8,591,897
Patent Owner: Genentech
Title:  Anti-ErbB2 Antibody Adjuvant Therapy

IPR2017-01726, filed by Pfizer

IPR2017-01727, filed by Pfizer

IPR2017-00959, filed by Celltrion

  • Filing date: February 21, 2017
  • Status: Terminated following Patent Owner request for adverse judgment on September 11, 2017.
  • Petition

U.S. Patent 6,339,142
Patent Owner: Genentech
Title: Protein Purification

IPR2017-02019, filed by Pfizer

IPR2018-00330, filed by Pfizer

U.S. Patent 9,249,218
Patent Owner:  Genentech
Title: Protein Purification

IPR2017-02020, filed by Pfizer

IPR2018-00331, filed by Pfizer

General Biologic Patents+

U.S. Patent 6,716,602
Patent Owner: Genentech
Title:  Metabolic Rate Shifts in Fermentations Expressing Recombinant Proteins

IPR2016-01608, filed by bioeq

U.S. Patent 9,051,556
Patent Owner: Shire
Title: Purification of iduronate-2-sulfatase

IPR2016-00258, filed by Green Cross Corp.

U.S. Patent 6,946,292
Patent Owner: Kyowa Kakko Kirin Co
Title:  Cells producing compositions with increased antibody dependent cytotoxic activity

IPR2017-01252, filed by Aragen Bioscience

U.S. Patent 8,067,232
Patent Owner: Kyowa Hakko Kirin Co.
Title: Antibody composition-producing cell with inactivated A-1, 6-fusocyltransferase

IPR2017-01254, filed by Aragen Bioscience

U.S. Patent 7,425,446
Patent Owner: Kyowa Hakko Kirin Co.
Title: Antibody composition-producing cell

IPR2017-01262, filed by Aragen Bioscience

U.S. Patent 7,332,289
Patent Owner: Chugai Pharmaceutical Co.
Title: Method of Purifying Protein

IPR2017-01357, filed by Pfizer

U.S. Patent 7,927,815
Patent Owner: Chugai Pharmaceutical Co.
Title: Protein Purification Method

IPR2017-01358, filed by Pfizer

U.S. Patent 6,870,034
Patent Owner: Genentech
Title:  Protein Purification

IPR2017-02029, filed by Boehringer Ingelheim

U.S. Patent 6,331,415
Patent Owner: Genentech
Title: Methods of producing immunoglobulins, vectors and transformed host cells for use therein

IPR2016-01373, filed by Merck Sharp & Dohme Corp.

IPR2016-00710, filed by Mylan

IPR2017-00047, filed by Merck Sharp & Dohme Corp.

IPR2016-00383, filed by Genyzme Corp.

IPR2015-01624, filed by Sanofi-Aventis

IPR2016-00460, filed by Genzyme

U.S. Patent 7,807,799
Patent Owner:  Genentech
Title:  Reducing protein A leaching Affinity Chromatography

IPR2016-01837, filed by Pfizer

This page is maintained by Lindsey Wanner.